What You Should Know:
- Sun Genomics raises $8.65M in Series A funding to scale
direct to consumer personalized probiotic solutions based on whole-genome sequencing
diagnostics.
- Flagship product Floré, a microbiome test, and gut probiotics solution utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product that is based on their unique gut profiles.
Sun Genomics, a San
Diego, CA-based
Read More
Sun Genomics and DexaFit Partner to Integrate Gut Health Testing
- Sun Genomics partners with DexaFit to integrate gut health testing to offer microbiome analysis and insights at 27 health and wellness clinics nationwide. - With the addition of Sun Genomics Floré testing, DexaFit is now incorporating microbiome analysis into its approach to give its clients a thorough understanding of their gut DNA or microbiome to further measure and improve their overall health and performance. Sun Genomics today announced that it is partnering with DexaFit, the
Read More
Sun Genomics Delivers Personalized Probiotics In Only 6 Weeks to Address Gut Health Issues
- Sun Genomics launches personalized probiotic solution to identify and address individual gut health issues to improve the health of millions of Americans. - Solution delivers precise probiotic formula required for each person to address their own unique gut health issues in just six weeks. - Sun Genomics Floré includes a kit to collect a micro-stool sample, a full microbiome analysis report, and a 90-day supply of precision probiotics.Sun Genomics today launched the first customized
Read More
BiomeSense Nabs $2M to Expand Daily Gut Microbiome Tracking Platform
- BiomeSense raises $2M in seed funding to expand its biosensor and analytics platform for daily gut microbiome tracking. - The company is working on completing its prototype biosensor and data modeling platform in preparation for the first clinical trials, scheduled for 2020.- The trials will investigate cancer progression, immunotherapy response, surgical recovery and athletic performance.BiomeSense, a Chicago, IL-based microbiome startup developing a novel biosensor and analytics platform for
Read More
Mayo Clinic to Leverage Viome’s Microbiome Analysis Platform in Study to Help Understand Sleep and Obesity
Mayo Clinic is collaborating on a study with Viome, a company transforming health through personalized nutrition based on individual biology to better understand the role of nutrition in disease and to explore the potential of Viome's AI-driven personalized diets in helping manage sleep disorders such as sleep apnea and obesity.
Understanding Microbiome
A person’s microbiome is the entire collection of microbes living in and on the body. The microbiome forms a living layer over your skin
Read More
LunaPBC Raises $4.6M to Fuel Community-Owned Genomic & Health Data Platform
LunaPBC, founder of LunaDNA, the first community-owned genomic and health data platform, has raised $4.6 million from ARCH Venture Partners, Bain Capital Ventures, F-Prime Capital, Illumina Ventures, and Osage University Partners. The latest round brings the company’s total funding to date to $7.6 million.
First Community-Owned Health & DNA Research Platform
Founded in 2017 on the belief that health data sharing and community ownership are the new philanthropy, LunaDNA is the first
Read More
Biotech Startup uBiome Raises $83M to Expand World’s Largest Human Microbiome Database
uBiome, a microbial genetics company leveraging artificial intelligence to develop wellness products, clinical tests, and therapeutics based on the microbiome, today announced it has raised $83 million in Series C funding. The round was led by OS Fund, with participation from 8VC, Y Combinator, Dentsu Ventures, and additional new and existing investors. Now, uBiome is mining its database (the world's largest human microbiome database) to discover new therapeutic targets, with an initial focus on
Read More
Ferring Acquires Microbiome Platform Rebiotix
Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group has acquired Rebiotix Inc., a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to transform the treatment of challenging diseases. This acquisition brings together two innovative healthcare companies that share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients. Rebiotix’s RBX2660 is a non-antibiotic treatment in
Read More
